ClinicalTrials.gg
CompletedNCT00424190cSSSIUpdated Mar 14, 2017Results posted

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

A Phase 3 interventional study of IV Vancomycin plus IV Aztreonam and Ceftaroline in Bacterial Infections, sponsored by Forest Laboratories. Completed at 52 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-14.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
698
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
13th of 151
698 · median 62
Started
2007
with 8 others
Phase 3
24 of 181
2 open now
Registered
25th of 181
by date
Lead sponsor
3 of 181
Forest Laboratories

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 13th largest by enrollment of the 151 interventional ones that give a count, is one of 9 that started in 2007, is one of 24 in phase 3, and was the 25th registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.

Read the detailed description

Additional purpose of the study is to compare ceftaroline effectivity versus Vancomycin plus Aztreonam in the treatment of complicated skin infections in adults.

03

Conditions studied

  • Bacterial Infections

Keywords

  • Abscess
  • Antibacterial
  • Antibiotic
  • Antimicrobial
  • Bacterial infection, skin
  • Ceftaroline
  • Ceftaroline acetate
  • Cellulitis
  • Cephalosporin
  • Complicated skin and skin structure infection
  • cSSSI
  • Intravenous
  • Methicillin-resistant Staphylococcus Aureus (MRSA)
  • PPI-0903
  • Prodrug
  • Skin disease, bacterial
  • Skin infection
  • Staphylococcal skin infection
  • Staphylococcus aureus
  • Streptococcal skin infection
  • Surgical site infection
  • TAK-599
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of current cSSSI with an antimicrobial.
  • Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
698 participants (actual)

Study arms

  • Experimental
    Ceftaroline for Injection

    Drug: Ceftaroline

  • Active comparator
    IV Vancomycin and IV Aztreonam

    Drug: IV Vancomycin plus IV Aztreonam

Interventions

  • DrugIV Vancomycin plus IV Aztreonam

    Drug pages: VancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AztreonamStudies of AztreonamAztreonam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.

    Also known as: Active Comparator

  • 600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days

    Also known as: Experimental

06

What researchers measure

Primary outcomes

  1. Clinical Cure Rate at Test of Cure (TOC) (MITT Population)

    Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary. Failure: Requirement of alternative antimicrobial therapy for primary infection of cSSSI due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI. Indeterminate: Inability to determine an outcome

    Time frame: 8-15 days after the end of treatment

  2. Clinical Cure Rate of Ceftaroline Compared With That of Vancomycin Plus Aztreonam Treatment at TOC in the Clinically Evaluable (CE) Population

    Time frame: 8-15 days after last dose of study drug

Secondary outcomes

  1. Microbiological Success Rate at the TOC Visit

    Time frame: 8-15 days after last dose of study drug

  2. Clinical Response at the End of Therapy (EOT) Visit

    Time frame: Last day of study drug administration

  3. Clinical and Microbiological Response by Pathogen at the TOC Visit

    Time frame: 8-15 days after last dose of study drug

  4. Clinical Relapse at the Late Follow Up (LFU) Visit

    Time frame: 21 to 35 days after the last dose of study drug

  5. Microbiological Reinfection or Recurrence at the LFU Visit

    Time frame: 21 to 35 days after the last dose of study drug

  6. Assess Safety

    Comparisons of the number of participants with Adverse Events

    Time frame: First dose of study drug through TOC visit

07

Results

Posted Nov 7, 2010

Participant flow

Patients were recruited worldwide from February 2007 to November 2007

Participant flow — Overall Study
MilestoneCeftaroline Fosamil for InjectionIV Vancomycin Plus IV Aztreonam
Started351347
Completed329317
Not completed2230
Withdrew: Withdrew consent34
Withdrew: Death30
Withdrew: Noncompliance12
Withdrew: Request of sponsor or investigator02
Withdrew: Diagnosis of osteomyelitis01
Withdrew: Other1521

Outcome measures

PrimaryClinical Cure Rate at Test of Cure (TOC) (MITT Population)

Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary. Failure: Requirement of alternative antimicrobial therapy for primary infection of cSSSI due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI. Indeterminate: Inability to determine an outcome

Time frame:
8-15 days after the end of treatment
Reported as:
Number · participants
Clinical Cure Rate at Test of Cure (TOC) (MITT Population)
participantsCeftaroline Fosamil for InjectionIV Vancomycin Plus IV Aztreonam
Clinical Cure304297
Clinical Failure2921
Indeterminate1829
Statistical analysis
  • Ceftaroline Fosamil for Injection vs IV Vancomycin Plus IV Aztreonam · Risk difference (rd): 1.0 · 95% CI -4.2 to 6.2Risk difference corresponds to Ceftaroline clinical cure rate minus Vancomycin plus Aztreonam clinical cure rate. The confidence interval was calculated using the Miettinen and Nurminen method without adjustment.
PrimaryClinical Cure Rate of Ceftaroline Compared With That of Vancomycin Plus Aztreonam Treatment at TOC in the Clinically Evaluable (CE) Population
Time frame:
8-15 days after last dose of study drug

Results for this outcome have not been posted.

SecondaryMicrobiological Success Rate at the TOC Visit
Time frame:
8-15 days after last dose of study drug

Results for this outcome have not been posted.

SecondaryClinical Response at the End of Therapy (EOT) Visit
Time frame:
Last day of study drug administration

Results for this outcome have not been posted.

SecondaryClinical and Microbiological Response by Pathogen at the TOC Visit
Time frame:
8-15 days after last dose of study drug

Results for this outcome have not been posted.

SecondaryClinical Relapse at the Late Follow Up (LFU) Visit
Time frame:
21 to 35 days after the last dose of study drug

Results for this outcome have not been posted.

SecondaryMicrobiological Reinfection or Recurrence at the LFU Visit
Time frame:
21 to 35 days after the last dose of study drug

Results for this outcome have not been posted.

SecondaryAssess Safety

Comparisons of the number of participants with Adverse Events

Time frame:
First dose of study drug through TOC visit

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ceftaroline Fosamil for Injection—16/351 (4.6%)128/351 (36.5%)
IV Vancomycin Plus IV Aztreonam—12/347 (3.5%)162/347 (46.7%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventCeftaroline Fosamil for InjectionIV Vancomycin Plus IV Aztreonam
CellulitisInfections and infestations2/3511/347
Cardiac failure congestiveCardiac disorders1/3511/347
Coronary artery diseaseCardiac disorders0/3511/347
ConstipationGastrointestinal disorders0/3511/347
Generalized edemaGeneral disorders0/3511/347
HypersensitivityImmune system disorders1/3511/347
Viral infectionInfections and infestations0/3511/347
Wound infectionInfections and infestations0/3511/347
Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3511/347
SyncopeNervous system disorders0/3511/347
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCeftaroline Fosamil for InjectionIV Vancomycin Plus IV Aztreonam
PruritusSkin and subcutaneous tissue disorders11/35129/347
NauseaGastrointestinal disorders20/35116/347
HeadacheNervous system disorders18/35113/347
Pruritus generalizedSkin and subcutaneous tissue disorders13/35116/347
DiarrheaGastrointestinal disorders12/35111/347
RashSkin and subcutaneous tissue disorders12/3518/347
VomitingGastrointestinal disorders9/3519/347
InsomniaPsychiatric disorders5/3519/347
PyrexiaGeneral disorders4/3519/347
ErythemaSkin and subcutaneous tissue disorders3/3519/347

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ceftaroline Fosamil for InjectionIV Vancomycin Plus IV AztreonamTotal
Mean49.2 ± 17.1747.2 ± 17.0148.2 ± 17.10
Age, Customized
Age, Customized(participants)Ceftaroline Fosamil for InjectionIV Vancomycin Plus IV AztreonamTotal
>=65 years5772129
<18 years000
>=18 years and < 65 years294275569
Sex: Female, Male
Sex: Female, Male(Participants)Ceftaroline Fosamil for InjectionIV Vancomycin Plus IV AztreonamTotal
Female131129260
Male220218438
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ceftaroline Fosamil for InjectionIV Vancomycin Plus IV AztreonamTotal
Non-Hispanic268270538
Hispanic8377160
08

Study locations

52 sites
  • Investigational Site
    Dothan, Alabama 36301, United States
  • Investigational Site
    Long Beach, California 90813, United States
  • Investigational Site
    Los Angeles, California 90015, United States
  • Investigational Site
    Sacramento, California 95817, United States
  • Investigational Site
    Sacramento, California 95819, United States
  • Investigational Site
    San Diego, California 92114, United States
  • Investigational Site
    San Francisco, California 94110, United States
  • Investigational Site
    Torrance, California 90509, United States
  • Investigational Site
    Savannah, Georgia 31405, United States
  • Investigational Site
    Naperville, Illinois 60540, United States
  • Investigational Site
    Indianapolis, Indiana 46280, United States
  • Investigational Site
    Shreveport, Louisiana 71103, United States
  • Investigational Site
    Columbus, Ohio 43215, United States
  • Investigational Site
    Landsdale, Pennsylvania 19446, United States
  • Investigational Site
    Tacoma, Washington 98405, United States
  • Investigational Site
    Buenos Aires, 164, Argentina
  • Investigational Site
    Buenos Aires, Argentina
  • Invetigational Site
    Buenos Aires, Argentina
  • Investigational Site
    Ciudad Autónoma de Buenos Aires, 1240 C1180AAX, Argentina
  • Investigational Site
    Cordoba, Argentina
  • Invetigational Site
    Cordoba, Argentina
  • Investigational Site
    Entre Rios, Argentina
  • Investigational Site
    Santa Fe, Argentina
  • Investigational Site
    Curiuba-Parans, 1089, Brazil
  • Investigational Site
    Sao Paulo, 04039-020, Brazil
  • Investigational Site
    Santiago, Chile
  • Investigational Site
    Vina del Mar, Chile
  • Investigational Site
    Berlin, D-10249, Germany
  • Investigational Site
    Bochum, 44791, Germany
  • Investigational Site
    Hanau, Germany
  • Investigational Site
    Plauen, 08529, Germany
  • Investigational Site
    Quedlinburg, 06484, Germany
  • Investigational Site
    Chihuahua, 31238, Mexico
  • Invetigational Site
    Lima, 29, Peru
  • Investigational Site
    Bytom, 41-902, Poland
  • Investigational Site
    Krakow, 31-913, Poland
  • Investigational Site
    Lublin, 20-081, Poland
  • Investigational Site
    Sosnowiec, 41-200, Poland
  • Investigational Site
    Todz, 91-425, Poland
  • Investigational Site
    Bucharest, 010816, Romania
  • Investigational Site
    Bucharest, 041915, Romania
  • Investigational Site
    Timisoara, 300736, Romania
  • Investigational Site
    Moscow, 105229, Russian Federation
  • Investigational Site
    Moscow, 111539, Russian Federation
  • Investigational Site
    Moscow, 129327, Russian Federation
  • Investigational Site
    Smolensk, 214019, Russian Federation
  • Investigational Site
    St. Petersburg, 192242, Russian Federation
  • Investigational Site
    St. Petersburg, 194354, Russian Federation
  • Investigational Site
    St. Petersburg, 196247, Russian Federation
  • Investigational Site
    Dnipropetrovsk, 49600, Ukraine
  • Investigational Site
    Ivano-Frankivsk, 76008, Ukraine
  • Investigational Site
    Lviv, 79659, Ukraine
09

References and documents

Publications

  • Dryden M, Kantecki M, Yan JL, Stone GG, Leister-Tebbe H, Wilcox M. Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials. J Glob Antimicrob Resist. 2022 Mar;28:108-114. doi: 10.1016/j.jgar.2021.10.027. Epub 2021 Dec 16. PubMed 34922058 ↗
  • Wilcox M, Yan JL, Gonzalez PL, Dryden M, Stone GG, Kantecki M. Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials. Infect Dis Ther. 2022 Feb;11(1):217-230. doi: 10.1007/s40121-021-00557-w. Epub 2021 Nov 6. PubMed 34741280 ↗
  • Corey GR, Wilcox MH, Gonzalez J, Jandourek A, Wilson DJ, Friedland HD, Das S, Iaconis J, Dryden M. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. Int J Antimicrob Agents. 2019 Jun;53(6):830-837. doi: 10.1016/j.ijantimicag.2019.01.016. Epub 2019 Feb 1. PubMed 30716446 ↗
  • Cheng K, Pypstra R, Yan JL, Hammond J. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. J Antimicrob Chemother. 2019 Apr 1;74(4):1086-1091. doi: 10.1093/jac/dky519. PubMed 30597021 ↗
  • Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv67-iv71. doi: 10.1093/jac/dkq256. PubMed 21115456 ↗
  • Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv41-51. doi: 10.1093/jac/dkq254. PubMed 21115454 ↗
  • Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827. PubMed 20695801 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2007
First posted
Jan 18, 2007
Start
Feb 2007
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Nov 7, 2010
Last update
Mar 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00424190
First posted
Jan 18, 2007
Start date
Feb 2007
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Nov 7, 2010
Last update
Mar 14, 2017

Study contacts

Ralph Corey, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceftaroline

Start the discussion